RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer

RNA N6-methyladenosine (m6A) methylation is known to be the most popular RNA modification in animals. Many research reports have elaborated on the effects of m6A regulators in medical practice, such as diagnosis, prognosis, and treatment. M6A modification has evident impacts on many aspects of RNA m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hao Su, Yutao Wang, Hongjun Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	m6A methylation muti-omics analysis prostate cancer vitro experiment. methylation prognosis model Genetics QH426-470
Acceso en línea:	https://doaj.org/article/c7c736a8c07c44088790dff9ef117285
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c7c736a8c07c44088790dff9ef117285
record_format	dspace
spelling	oai:doaj.org-article:c7c736a8c07c44088790dff9ef1172852021-12-01T07:17:37ZRNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer1664-802110.3389/fgene.2021.768041https://doaj.org/article/c7c736a8c07c44088790dff9ef1172852021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fgene.2021.768041/fullhttps://doaj.org/toc/1664-8021RNA N6-methyladenosine (m6A) methylation is known to be the most popular RNA modification in animals. Many research reports have elaborated on the effects of m6A regulators in medical practice, such as diagnosis, prognosis, and treatment. M6A modification has evident impacts on many aspects of RNA metabolism, just like RNA splicing, processing, translation, and stability. M6A also has a magnificent role in numerous types of cancers. We analyzed the prostate cancer datasets, from The Cancer Genome Atlas (TCGA) database, for every recognized m6A regulator in their gene expression, DNA methylation status and copy number variations (CNVs). We also systematically analyzed the relationship between different m6A regulators and the prognosis of prostate cancer. The results illustrated considerable differences in the expression of various m6A regulators between the prostate and normal cancer samples. At the same time, there were evident differences in the expression of various m6A regulators in prostate cancers with different Gleason scores. Subsequently, we determined CBLL1, FTO, YTHDC1, HNRNPA2B1 as crucial m6A regulators of prostate cancer. Premised on the expression of CBLL1, we also identified potential therapeutic agents for prostate cancer, and knockdown of HNRNPA2B1 prominently inhibited prostate cells migration and invasion in vitro experiment.Hao SuYutao WangHongjun LiFrontiers Media S.A.articlem6A methylationmuti-omics analysisprostate cancervitro experiment.methylation prognosis modelGeneticsQH426-470ENFrontiers in Genetics, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	m6A methylation muti-omics analysis prostate cancer vitro experiment. methylation prognosis model Genetics QH426-470
spellingShingle	m6A methylation muti-omics analysis prostate cancer vitro experiment. methylation prognosis model Genetics QH426-470 Hao Su Yutao Wang Hongjun Li RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer
description	RNA N6-methyladenosine (m6A) methylation is known to be the most popular RNA modification in animals. Many research reports have elaborated on the effects of m6A regulators in medical practice, such as diagnosis, prognosis, and treatment. M6A modification has evident impacts on many aspects of RNA metabolism, just like RNA splicing, processing, translation, and stability. M6A also has a magnificent role in numerous types of cancers. We analyzed the prostate cancer datasets, from The Cancer Genome Atlas (TCGA) database, for every recognized m6A regulator in their gene expression, DNA methylation status and copy number variations (CNVs). We also systematically analyzed the relationship between different m6A regulators and the prognosis of prostate cancer. The results illustrated considerable differences in the expression of various m6A regulators between the prostate and normal cancer samples. At the same time, there were evident differences in the expression of various m6A regulators in prostate cancers with different Gleason scores. Subsequently, we determined CBLL1, FTO, YTHDC1, HNRNPA2B1 as crucial m6A regulators of prostate cancer. Premised on the expression of CBLL1, we also identified potential therapeutic agents for prostate cancer, and knockdown of HNRNPA2B1 prominently inhibited prostate cells migration and invasion in vitro experiment.
format	article
author	Hao Su Yutao Wang Hongjun Li
author_facet	Hao Su Yutao Wang Hongjun Li
author_sort	Hao Su
title	RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer
title_short	RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer
title_full	RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer
title_fullStr	RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer
title_full_unstemmed	RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer
title_sort	rna m6a methylation regulators multi-omics analysis in prostate cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c7c736a8c07c44088790dff9ef117285
work_keys_str_mv	AT haosu rnam6amethylationregulatorsmultiomicsanalysisinprostatecancer AT yutaowang rnam6amethylationregulatorsmultiomicsanalysisinprostatecancer AT hongjunli rnam6amethylationregulatorsmultiomicsanalysisinprostatecancer
_version_	1718405442795732992

RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer

Ejemplares similares